Novavax(US:NVAX)2025-05-08 12:41Financial Performance - Total revenue for Q1 2025 reached $667 million[23], a significant increase compared to $94 million in Q1 2024[27] - Nuvaxovid sales contributed $608 million[27] to the total revenue, including $603 million related to the termination of two APAs[30] - The company reported a net income of $519 million[31] in Q1 2025, a substantial turnaround from a net loss of $148 million in Q1 2024[31] - Combined R&D and SG&A expenses decreased by 24% to $137 million in Q1 2025, compared to $180 million in Q1 2024[32] - Current liabilities were reduced by $732 million in Q1 2025[23], resulting in a current liability balance of $0.4 billion[34] Strategic Priorities and Partnerships - The company is prioritizing its partnership with Sanofi[11], expecting up to $225 million in milestones in 2025[25] - Adjusted total revenue for full year 2025 is projected to be between $975 million and $1025 million[42] - Adjusted licensing, royalties, and other revenue are expected to be between $345 million and $380 million[42], including $225 million in U S BLA & Marketing Authorizations Milestones[44] R&D and Pipeline - The company's Matrix-M adjuvant has a favorable reactogenicity profile, supported by over 60 publications[14] - Nuvaxovid recipients experienced approximately 39% fewer symptoms on average compared to mRNA vaccines[18] - The company is diversifying its R&D pipeline, including combination vaccines for COVID-19 and seasonal influenza (CIC)[21]